Pacer Advisors Inc. lowered its position in Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 1.8% during the 1st quarter, Holdings Channel reports. The fund owned 14,648 shares of the medical instruments supplier’s stock after selling 275 shares during the period. Pacer Advisors Inc.’s holdings in Becton, Dickinson and were worth $3,896,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in BDX. Accel Wealth Management boosted its holdings in Becton, Dickinson and by 100.0% in the fourth quarter. Accel Wealth Management now owns 100 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 50 shares in the last quarter. Sierra Capital LLC boosted its holdings in Becton, Dickinson and by 88.7% in the fourth quarter. Sierra Capital LLC now owns 100 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares in the last quarter. Level Financial Advisors Inc. bought a new position in Becton, Dickinson and in the fourth quarter worth approximately $26,000. Fortis Advisors LLC bought a new position in Becton, Dickinson and in the third quarter worth approximately $27,000. Finally, EverSource Wealth Advisors LLC bought a new position in shares of Becton, Dickinson and in the fourth quarter valued at approximately $37,000. Institutional investors and hedge funds own 86.58% of the company’s stock.
BDX has been the topic of a number of recent research reports. Piper Sandler dropped their target price on Becton, Dickinson and from $265.00 to $255.00 in a report on Thursday, May 5th. Bank of America began coverage on Becton, Dickinson and in a report on Tuesday, March 1st. They issued a “neutral” rating on the stock. StockNews.com lowered Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Tuesday, June 14th. Morgan Stanley lifted their price target on Becton, Dickinson and from $293.00 to $295.00 and gave the stock an “overweight” rating in a report on Monday, April 11th. Finally, Argus lifted their price target on Becton, Dickinson and from $275.00 to $310.00 in a report on Monday, February 28th. Six investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Becton, Dickinson and currently has an average rating of “Hold” and a consensus price target of $280.83.
NYSE:BDX opened at $237.27 on Thursday. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.52 and a quick ratio of 1.04. The business has a fifty day simple moving average of $252.17 and a two-hundred day simple moving average of $258.20. Becton, Dickinson and Company has a 1 year low of $231.46 and a 1 year high of $280.62. The company has a market capitalization of $67.64 billion, a P/E ratio of 37.42, a P/E/G ratio of 3.18 and a beta of 0.64.
Becton, Dickinson and (NYSE:BDX – Get Rating) last released its earnings results on Thursday, May 5th. The medical instruments supplier reported $3.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.98 by $0.20. Becton, Dickinson and had a return on equity of 14.91% and a net margin of 9.59%. The business had revenue of $5.01 billion during the quarter, compared to the consensus estimate of $4.78 billion. During the same period last year, the business posted $3.19 earnings per share. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. As a group, analysts anticipate that Becton, Dickinson and Company will post 11.2 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, June 30th. Shareholders of record on Thursday, June 9th will be given a $0.87 dividend. This represents a $3.48 dividend on an annualized basis and a yield of 1.47%. The ex-dividend date of this dividend is Wednesday, June 8th. Becton, Dickinson and’s dividend payout ratio is currently 54.89%.
Becton, Dickinson and Profile (Get Rating)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
- Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Victoria’s Secret Stock is Out of the Box
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.